{
	"assertions": [
		{
			"id": 71,
			"context": "",
			"description": "T315I mutant ABL1 in p210 BCR-ABL cells resulted in retained high levels of phosphotyrosine at increasing concentrations of inhibitor STI-571, whereas wildtype appropriately received inhibition.",
			"disease": {
				"name": "Chronic Myelogenous Leukemia",
				"oncotree_code": "CML",
				"oncotree_term": "Chronic Myelogenous Leukemia"
			},
			"therapy_name": "Imatinib",
			"therapy_type": "Targeted therapy",
			"clinical_significance": "resistance",
			"predictive_implication": "Preclinical",
			"favorable_prognosis": false,
			"created_on": "09/08/22",
			"last_updated": "2019-06-13",
			"submitted_by": "breardon@broadinstitute.org",
			"validated": true,
			"source_ids": 44,
			"variant": {
				"id": 71,
				"alternate_allele": "T",
				"cdna_change": "c.944C>T",
				"chromosome": "9",
				"end_position": "133747580",
				"exon": "5",
				"feature_type": "somatic_variant",
				"gene": "ABL1",
				"protein_change": "p.T315I",
				"reference_allele": "C",
				"rsid": null,
				"start_position": "133747580",
				"variant_annotation": "Missense",
				"feature": "ABL1 p.T315I (Missense)"
			}
		}
	],
	"sources": [
		{
			"id": 44,
			"type": "Journal",
			"doi": "10.1126/science.1062538",
			"nct": "",
			"pmid": 11423618,
			"url": "https://doi.org/10.1126/science.1062538",
			"citation": "Gorre, Mercedes E., et al. \"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.\" Science 293.5531 (2001): 876-880."
		}
	],
	"variants": [
		{
			"id": 71,
			"alternate_allele": "T",
			"cdna_change": "c.944C>T",
			"chromosome": "9",
			"end_position": "133747580",
			"exon": "5",
			"feature_type": "somatic_variant",
			"gene": "ABL1",
			"protein_change": "p.T315I",
			"reference_allele": "C",
			"rsid": null,
			"start_position": "133747580",
			"variant_annotation": "Missense",
			"feature": "ABL1 p.T315I (Missense)"
		}
	],
	"genes": [
		"ABL1"
	]
}